

1 **The development and validation of multiplex real-time PCRs with fluorescent melting**  
2 **curve analysis for simultaneous detection of six bacterial pathogens of lower respiratory**  
3 **tract infections and antimicrobial resistance genes.**

4  
5 Tran Thi Ngoc Dung,<sup>1</sup> Voong Vinh Phat,<sup>1</sup> Chau Vinh,<sup>1</sup> Nguyen Phu Huong Lan,<sup>2</sup> Nguyen Luong  
6 Nha Phuong,<sup>2</sup> Le Thi Quynh Ngan,<sup>2</sup> Guy Thwaites,<sup>1,3</sup> Louise Thwaites<sup>1,3</sup>, Maia Rabaa,<sup>1,3</sup> Nguyen  
7 Thi Kim Anh<sup>1,2</sup>, Pham Thanh Duy<sup>1\*</sup>

8  
9 <sup>1</sup> Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

10 <sup>2</sup> Hospital For Tropical Diseases, Ho Chi Minh City, Vietnam

11 <sup>3</sup> Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,  
12 Oxford University, United Kingdom

13  
14  
15 \*Correspondence. Pham Thanh Duy, Molecular Epidemiology Group, Oxford University Clinical  
16 Research Unit, Vietnam. 764 Vo Van Kiet street, Ward 1, District 5, HCMC, Vietnam; Email:  
17 [duypt@oucru.org](mailto:duypt@oucru.org). Phone: +84769.606.504. Fax: +84 8 39238904.

18  
19  
20  
21 Key words

22 Real-time PCRs, lower respiratory tract infections, antimicrobial resistance, melting curve  
23 analysis, molecular diagnostics.

24  
25  
26  
27  
28  
29  
30

31 **Abstract**

32 *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Escherichia coli*,  
33 *Streptococcus pneumoniae* and *Staphylococcus aureus* are among the major bacterial  
34 causative agents of lower respiratory tract infections (LRTIs), causing substantial morbidity and  
35 mortality globally. The rapid increase of antimicrobial resistance (AMR) in these pathogens  
36 poses significant challenges for effective antibiotic therapy of LRTIs. In low-resourced settings,  
37 the diagnostics of LRTIs relies heavily on microbiological culture and patients are often treated  
38 with empirical antibiotics while awaiting several days for culture results. Rapid detection of  
39 LRTIs pathogens and AMR genes could prompt early antibiotic switching and inform antibiotic  
40 treatment duration. In this study, we developed multiplex quantitative real-time PCRs using  
41 EvaGreen dye and melting curve analysis (MCA) to rapidly identify the six major LRTIs  
42 pathogens and their AMR genes directly from the tracheal aspirate and sputum samples. The  
43 accuracy of RT-PCRs was assessed by comparing its performance against the gold standard,  
44 conventional culture method on 50 tracheal aspirate and sputum specimens. Our RT-PCR  
45 assays had 100% sensitivity for *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *E. coli* and 63.6%  
46 for *S. aureus* and the specificity ranked from 87.5% to 97.6%. The kappa correlation values of  
47 all pathogens between the two methods varied from 0.63 to 0.95. The limit of detection (LOD) of  
48 target bacteria in multiplex RT-PCRs was 1600 CFU/mL. Compared to the culture results, PCR  
49 assays exhibited higher sensitivity in detecting mixed infections and *S. pneumoniae*. Our  
50 findings also demonstrated a high level of concordance between the detection of AMR gene and  
51 AMR phenotype in single infections. We conclude that our multiplex quantitative RT-PCRs with  
52 fluorescence MCA is simple but sensitive and specific in detecting six major drug resistant  
53 bacterial pathogens of LRTIs and should be further evaluated for clinical utility.

54

55

56

57

58

59

## 60 Introduction

61 Lower respiratory tract infections (LRTIs) are the leading infectious cause of morbidity and  
62 mortality globally. It is estimated that 336 million episodes of LRTIs occurred in 2016, resulting  
63 in nearly 2.4 million deaths of all ages and 652,000 deaths in children less than 5 years<sup>1</sup>.

64 Although viruses such as influenza virus and respiratory syncytial virus (RSV) are responsible  
65 for a largest proportion of LRTIs, most deaths are caused by bacterial agents, including  
66 *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, *Pseudomonas*  
67 *aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli* and *Acinetobacter baumannii*<sup>2-4</sup>.

68 In recent years, the worldwide increase of antimicrobial resistance (ARM) in respiratory bacterial  
69 pathogens threatens the effectiveness of antibiotic treatment<sup>5</sup>. Multidrug-resistant (MDR) Gram-  
70 negative pathogens are more frequently identified from patients with LRTIs, especially in ICUs,  
71 leading to increased risks of poor outcome, prolonged hospital stay, and mortality<sup>6</sup>. Early and  
72 rapid detection of LRTIs pathogens and its AMR phenotype is key to inform appropriate  
73 antibiotic therapy and reduce risks of severe complications and mortality among LRTI patients  
74 <sup>3,7,8</sup>.

75 Currently, a variety of traditional diagnostic methods are used to detect respiratory pathogens,  
76 including microscopic examination, bacterial culture, and antigen detection<sup>9</sup>. These methods  
77 often require a collection of various specimens with low sensitivity and long turnaround time<sup>9</sup>.  
78 Recently, several molecular PCR-based assays have been developed for the diagnostics of  
79 respiratory pathogens. Luminex assays and TaqMan array cards can detect many viruses and  
80 bacteria simultaneously<sup>10,11</sup>. The BioFire FilmArray Pneumonia Panel and Pneumonia Plus  
81 Panel can detect 18 bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 AMR  
82 markers, and 9 viruses that cause pneumonia<sup>12</sup>. However, the BioFire FilmArray assays are  
83 expensive and may not be adopted for routine diagnostics, particularly in low- and middle-  
84 income (LMIC) settings<sup>13</sup>.

85 Alternatively, multiplex real-time PCR with either fluorescent probe or fluorescent dye targeting  
86 key locally relevant bacterial-AMR gene combinations can provide a pragmatic and inexpensive  
87 diagnostic method for clinical utility. Compared to probe-based assay, dye-based assay with  
88 melting curve analysis (MCA) is less expensive and can detect more targets. The most  
89 commonly and successfully used fluorescent dye for multiplex real-time PCR is SYBR Green.  
90 However, recently, EvaGreen (EG) dye, a third-generation, new saturating fluorescent dye are  
91 proved to be better than SYBR Green due to EG dye can be used at higher concentrations

92 without inhibiting PCR and shows equal binding affinity for GC-rich and AT-rich regions<sup>14</sup>. EG-  
93 based multiplex real-time PCR with melting curve analysis has been developed for the detection  
94 of multiple bacterial pathogens of respiratory infections<sup>15,16</sup>.

95 Here, our study aimed to develop and validate multiplex real-time PCR with EvaGreen MCA  
96 assays (EG-mPCR assays) to detect six bacteria (4 Gram negative and 2 Gram positive) and  
97 fourteen AMR genes directly from respiratory specimens.

## 98 **Materials and methods**

### 99 **Bacteria strains**

100 To develop and validate our EG-mPCR assays, ATCC strains, clinical strains and off-target  
101 controls (*Acinetobacter lwoffii*, *Staphylococcus epidermidis*, *Shigella sonnei*, *Salmonella typhi*,  
102 *Campylobacter jejuni*) were utilized. Standard strains of *E. coli* (ATCC25922), *K. pneumoniae*  
103 (ATCC700603), *S. pneumoniae* (ATCC49619), *S. aureus* (ATCC25923), *P. aeruginosa*  
104 (ATCC27853) were purchased from the American Type Culture Collection (ATCC, Manassas,  
105 VA, USA) and subsequently cultured in Luria-Bertani (LB) agar or nutrient agar (NA). Further,  
106 eight clinical strains carrying the target AMR genes were used as positive controls for AMR  
107 gene detection assays.

### 108 **Clinical samples preparation**

109 Tracheal aspirate (TA) or sputum samples were collected from patients admitted to Hospital of  
110 Tropical Diseases in HCMC and sent to the Microbiology Department at Hospital for Tropical  
111 Diseases for routine microbiological diagnostics. Residual samples were transferred to the  
112 Molecular Laboratory at Oxford University Clinical Research Unit (OUCRU) for the evaluation of  
113 the EG-mPCR assays.

114

### 115 **Microbiological Culture**

116 The TA and the sputum samples were collected into a sterile container, followed by Gram  
117 staining and examination under direct microscopy. The samples having <10 epithelial cells and  
118 >25 leukocytes in each area upon 100x magnification were considered good quality for bacterial  
119 culture and were included in our study. Samples passing quality checking were liquefied with  
120 Sputasol liquid (Oxoid, USA) with ratio 1:1 and diluted with MRD broth (maximum recovery

121 diluent) with ratio 1:9 before microbiological testing. Subsequently, 1  $\mu$ l of suspension were  
122 inoculated into blood agar, Macconkey agar and chocolate agar media (Oxoid, USA), and  
123 incubated for 24-48 hours at 35-37°C or at 35-37°C with ~5% CO<sub>2</sub>. Bacterial identification and  
124 antimicrobial susceptibility testing (AST) was performed using Vitek2 automatic identification  
125 and AST system (Biomérieux, France). In TA culture, sample with bacterial growth  $\geq 10^5$   
126 CFU/mL was considered positive following the local guidelines for microbiological diagnostics.

## 127 **Extraction of nucleic acids**

128 DNA extraction from bacterial isolates was performed using the Wizard Genomic DNA  
129 Extraction Kit (Promega, Fitchburg, USA) according to the manufacturer's instructions. The  
130 quality and concentration of the DNA was assessed using a Nano-drop spectrophotometer prior  
131 to PCR amplification.

132 For TA/sputum samples, an aliquot of 200  $\mu$ l was homogenized with 4 times the volume of 0.1%  
133 dithiothreitol (DTT) for 15 minutes at room temperature and centrifuged at 8000 rpm for 10  
134 minutes. Subsequently, supernatant was discarded and pellet was resuspended with 200  $\mu$ l  
135 PBS. Next, 25  $\mu$ l of 10X buffer (200mM Tris-HCl, 0.2  $\mu$ l of Benzonase (Sigma) and 24.8  $\mu$ l of  
136 sterilized water) were added, followed by 2-hour incubation at 37°C. The mixture was  
137 centrifuged at 8000 rpm for 10 minutes and the pellet was subsequently resuspended in a  
138 mixture of 4  $\mu$ l EDTA, 120  $\mu$ l NaCl and 76  $\mu$ l H<sub>2</sub>O. Centrifugation was performed again at 8000  
139 rpm for 10 minutes and pellet was resuspended in 200  $\mu$ l of TE before DNA extraction. 200  $\mu$ l of  
140 pre-treated samples was subjected to an automated extraction on a MagNA Pure 96 nucleic  
141 extraction system (Roche applied sciences, UK), according to the manufacturers  
142 recommendations.

## 143 **Primer Design**

144 Twenty primer sets were designed based on the conserved regions which can produce  
145 amplicons having melting temperatures ( $T_m$ s) ranging from 75°C to 92°C and target-specific  $T_m$   
146 values differed from each other by at least 1°C. The primer sequences and their optimal  
147 concentrations are described in Table 1. The actual  $T_m$  of all primers was determined following  
148 the performance of singleplex PCRs and multiplex PCRs.

149

150 For simultaneous detection of the six LRTIs pathogens, six primer pairs were designed targeting  
151 the known species-specific genes that have been published previously (*yaiO* for *E. coli*<sup>17</sup>; *ompA*  
152 for *A. baumannii*<sup>18</sup>; *oatA* for *P. aeruginosa*<sup>19</sup>; *sa442* for *S. aureus*<sup>16</sup>; *ply* for *S. pneumoniae*<sup>16</sup>  
153 and *khe* for *K. pneumoniae*<sup>19</sup>. Additionally, fourteen primers were also designed to identify  
154 fourteen common acquired AMR genes present in these bacteria, encoding resistance to  $\beta$ -  
155 lactams (*bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, *bla*<sub>CTX-M-9</sub>, *bla*<sub>CTX-M-1</sub>), methicillin (*mecA*), carbapenems (*bla*<sub>KPC</sub>, *bla*<sub>NDM</sub>,  
156 *bla*<sub>OXA-48</sub>, *bla*<sub>OXA-23</sub>, *bla*<sub>IMP</sub>), colistin (*mcr-1*), macrolides (*ermB*, *mphA*) and vancomycin (*vanA*).

## 157 **Development of EG-mPCR assays**

158 Singleplex real-time PCR assays were performed in 20 $\mu$ l reaction volume, which included 5 $\mu$ l  
159 DNA template, 0.8 $\mu$ l forward and reverse primers and 10 $\mu$ l SensiFAST HRM kit (Meridian  
160 Bioscience), to check the actual  $T_m$ s of each individual target amplicon. Sterile purified water  
161 was used as the negative control. PCR amplifications were run on a LightCycler 480II (Roche  
162 applied sciences, UK) with the following thermal conditions: initial denaturation at 95°C for 5min,  
163 followed by 40 cycles of denaturation, 95°C, for 10 s; annealing, 60°C for 30 s; extension, 72°C  
164 for 30s. For multiplex real-time PCR assays, the component and thermal condition were the  
165 same as singleplex real-time PCRs, except the concentration of each primer pair varied from  
166 0.25  $\mu$ M to 0.5  $\mu$ M. After PCR amplification, the melting curve analysis (MCA) was conducted in  
167 the same thermocycler at 65°C to 95°C; and cooling cycle at 37°C for 30 s. Fluorescence was  
168 continuously measured and the melting temperature ( $T_m$ ) was calculated by plotting the  
169 negative derivative of fluorescence over temperature versus temperature ( $-dF/dT$  versus  $T$ ).  
170 Conventional PCRs with a different set of primers were later performed to confirm the results of  
171 EG-mPCR assays.

172 The reproducibility, linearity, limit of detection (LOD) of EG-mPCR assays for pathogen  
173 detection were evaluated using 5-fold serial dilutions of two DNA control mixes. Each DNA  
174 control mix was prepared by pooling equal volume of 10<sup>8</sup> CFU/mL of each bacterium, followed  
175 by DNA extraction. Subsequently, 5-fold serially diluted DNA standards, corresponding to the  
176 bacterial concentrations from 10<sup>6</sup> to 12.8 CFU/mL, were prepared for the assays.

177 To validate the assays in TA specimen, 200 $\mu$ l pre-treated culture-negative TA specimen was  
178 spiked with 5-fold serial dilutions of bacteria (from 10<sup>6</sup> to 12.8 CFU/mL), followed by DNA

179 extraction using Roche's MagNA Pure 96 system. The EG-mPCR assays were performed as  
180 described above.

### 181 **Diagnostic performance of EG-mPCR assays in comparison to conventional culture.**

182 Fifty TA and sputum samples were diagnosed using both the EG-mPCR assays and  
183 conventional microbiological culture and the results were compared between the two methods.  
184 The samples that were culture-negative but EG-mPCR positive were further confirmed by  
185 singleplex EG-PCR and conventional PCR. In addition, the correlation between the presence of  
186 AMR gene and AMR phenotype was also examined. The degree of agreement between EG-  
187 mPCR assays and conventional culture for bacterial identification was measured by Cohen's  
188 kappa<sup>20</sup>.

### 189 **Ethic statement**

190 The study did not collect patient's information or require taking additional samples from patients.  
191 Informed consent is waved by the Institutional Ethical Review Committee of Hospital of Tropical  
192 Diseases in Ho Chi Minh city.

## 193 **RESULTS**

### 194 **Detection of six bacteria and AMR genes by EG-mPCR assays**

195 Two EG-mPCR assays were used to detect 6 bacterial pathogens and additional three EG-  
196 mPCR assays were used to detect 14 AMR genes (Table 1). In each EG-mPCR assay, the  
197 melting curve analysis showed distinct T<sub>m</sub> peaks corresponding to the target bacteria and AMR  
198 genes, while negative controls did not show any signal (Figure 1). The difference between two  
199 consecutive peaks was more than 2°C (Table 2). There was no interference and cross-reactivity  
200 in our EG-mPCR assays. We additionally evaluated our assays on other closely related bacteria  
201 and did not find any non-specific signal for *Salmonella* Typhi, *Campylobacter jejuni*,  
202 *Acinetobacter Iwoffii*, *Staphylococcus epidermidis*. However, the *yaiO* primer which was  
203 supposed to be specific to *E. coli*, gave false positive signal for one *Shigella sonnei* isolate.

### 204 **Reproducibility, quantification and LOD of the two EG-mPCR assays for bacterial** 205 **identification**



206 The reproducibility of EG-mPCR assays was evaluated by accessing  $T_m$  values in inter and  
207 intra-assays. The standard deviation (SD) and coefficient variation (CV) of  $T_m$  were calculated  
208 in 5 replicates within the same run (intra-assay) and across 5 different runs (inter-assay). The  
209 intra-assay CV of each of the target bacteria ranged from 0.1% to 0.4% and the inter-assay CV  
210 ranged from 0.3% to 0.5%. Similarly, intra-assay CV and inter-assay CV of each of the target  
211 AMR genes varied from 0.04% to 0.57% and from 0.51% to 0.92%, respectively (Table 2).  
212 These data indicated good reproducibility of  $T_m$  values in our assays.

213 The standard curve for each bacterium in the two EG-mPCR assays was obtained by plotting  
214 the fluorescence intensity ( $-dF/dT$ ) or the height of the peak ( $y$ -axis) values against the  $\log_{10}$  of  
215 the bacterial concentrations ( $x$ -axis) inferred from the serially diluted DNA control mixes. The  
216 coefficient of determination of linear regression model of standard curves were  $R^2=0.92$  for *S.*  
217 *aureus*,  $R^2=0.92$  for *S. pneumoniae*,  $R^2=0.91$  for *E. coli*,  $R^2=0.97$  for *A. baumannii*,  $R^2=0.98$  for  
218 *K. pneumoniae* and  $R^2=0.95$  for *P. aeruginosa*. These data indicated a good linear correlation  
219 between the fluorescence values and the  $\log_{10}$  of bacterial concentration over a range of  
220 bacterial concentrations.

221 The limit of detection (LOD) was evaluated by observing the  $T_m$  peaks of each bacterium in the  
222 two serially diluted DNA control mixes. The experiment was performed in 5 replicates within the  
223 same run and in 10 replicates between different runs. Based on the lowest concentration of a  
224 target bacterium in a control mix where all targets showed positive signal, a LOD of 1600  
225 CFU/mL was identified for each of the two EG-mPCR assays (Figure 2). When a TA specimen  
226 was spiked with target bacteria, a LOD of 3200 CFU/mL was identified for each of the two EG-  
227 mPCR assays.

## 228 **Diagnostic performance of EG-mPCR assays in comparison to conventional culture**

229 Between December 2020 and March 2021, 50 consecutive TA and sputum specimens were  
230 included for both conventional culture and EG-mPCR assays. Conventional culture showed that  
231 76% (38/50) of samples were culture positive for single target pathogen and 16% (8/50) were  
232 culture positive for more than one pathogen (including 4 pathogens not covered in the PCR  
233 detection assays: *Haemophilus influenzae*, *Moraxella*, *Stenotrophomonas maltophilia*,  
234 *Enterobacter*). *P. aeruginosa* was the most prevalent pathogen (26%, 13/50), followed by *A.*  
235 *baumannii* (20%, 10/50), *S. aureus* (18%, 9/50), *K. pneumoniae* (12%, 6/50) and *E. coli* (2%,



236 1/50) (Table 4). Three samples (6%) were culture negative for all six pathogens. Overall, the  
237 microbiological culture from TA and sputum samples yielded a total of 51 target pathogens.

238 According EG-mPCR results, 56% (28/50) of samples had one peak with strong fluorescence  
239 signal and were identified as single infections. There were 18 samples (36%) showed at least 2  
240 melting curve peaks with strong fluorescence signals, which were identified as co-infections.  
241 The most common patterns of co-infections detected by PCR were *P. aeruginosa* and *S.*  
242 *pneumoniae* (3/18) and *P. aeruginosa* and *S. aureus* (3/18), *P. aeruginosa* and *K. pneumoniae*  
243 (2/18) and *P. aeruginosa* and *A. baumannii* (2/18). *P. aeruginosa* (12/18) was the most common  
244 pathogen detected in co-infections (Figure 3). EG-mPCR showed negative results in 4 samples,  
245 three of which were also culture negative. Overall, EG-mPCR assays yielded a total of 67 target  
246 pathogens.

247 Compared to conventional culture, the sensitivity and specificity of EG-mPCR assays for *K.*  
248 *pneumoniae*, *A. baumannii*, *P. aeruginosa*, *E. coli*, *S. aureus* were 100% and 97.5%, 100% and  
249 97.2%, 100% and 87.5%, 100% and 93.8%, 63.6% and 94.9%, respectively (Table 3). The  
250 positive predictive value (PPV) and negative predictive value (NPV) of EG-mPCR assays were  
251 90.9% and 100% for *K. pneumoniae*, 93.3% and 100% for *A. baumannii*, 81.8% and 100% for  
252 *P. aeruginosa*, 50% and 100% for *E. coli* and 77.8% and 90.2% for *S. aureus*, respectively.

253 Out of the microbiologically-confirmed 51 target pathogens, 48 pathogens (94.1%) were also  
254 detected by EG-mPCR assays with a quantitative result  $\geq 10^5$  CFU/mL, which is a cut off of  
255 culture positivity (Figure 4A). Our data demonstrated a high degree of similarity between EG-  
256 mPCR assays and culture method. When considering only microbiologically-confirmed target  
257 pathogens with growth  $\geq 10^5$  CFU/mL ( $n=26$ ) in TA samples, concordant PCR-based  
258 quantitative results were found in 100% (11/11) of *A. baumannii*, 100% (1/1) of *E. coli*, 100%  
259 (5/5) of *K. pneumoniae*, 100% (8/8) of *P. aeruginosa* and 100% (1/1) of *S. aureus* (Figure 4B).  
260 There were however discordant results between the two methods. The culture method did not  
261 grow any *S. pneumoniae* isolates whereas the PCR assay found 6 *S. pneumoniae* with a  
262 quantity ranging from  $10^{3.6}$  to  $10^9$  CFU/mL; furthermore, the culture failed to detect another 10  
263 target bacteria that were identified by PCR (8 bacteria with a quantity  $\geq 10^5$  CFU/mL and 2  
264 bacteria with a quantity  $<10^5$  CFU/mL) (Figure 4A). Consequently, a total of 26 isolates were  
265 identified by PCR as mixed infections, for which only 11 isolates were identified by culture  
266 method as single infections and 15 isolates were missing from the culture results.

## 267 Application of EG-mPCR assays for AMR gene detection from clinical samples

268 Three EG-mPCR assays were used to identify 14 AMR genes commonly present in the target  
269 pathogens from 50 clinical samples. After excluding mixed infections by PCR, the level of  
270 correlation between the presence of AMR gene and AMR phenotype was assessed in 28 target  
271 bacteria. The overall distribution of AMR genes and AMR profiles of 28 target bacteria are  
272 shown in Table 4 and Figure 6. In *A. baumannii*, 100% (7/7) of the isolates carried *bla*<sub>OXA23</sub> and  
273 *bla*<sub>TEM</sub> were resistant to ceftazidime, cefepime and carbapenem (imipenem, meropenem).  
274 Among 4 *K. pneumoniae* isolates that were resistant to 3<sup>rd</sup> and 4<sup>th</sup>- generation cephalosporins  
275 (ceftriaxone, cefotaxime, cefepime), *bla*<sub>CTX-M-1</sub> was found in all 4 isolates and *bla*<sub>TEM</sub> was found in  
276 3/4 isolates. *Bla*<sub>NDM</sub> and *bla*<sub>OXA48</sub> genes were both detected in two carbapenem resistant *K.*  
277 *pneumoniae* isolates. For *P. aeruginosa*, *bla*<sub>OXA23</sub> was found in one isolate that was resistant to  
278 imipenem and meropenem and *bla*<sub>CTX-M-9</sub> was found in another isolate that was resistant to the  
279 3<sup>rd</sup> generation cephalosporin (ceftriaxone, cefotaxime). Among five *S. aureus* isolates that were  
280 resistant to macrolides (clindamycin), *emrB* gene was detected in 3 isolates (60%). Two isolates  
281 (1 *K. pneumoniae* and 1 *A. baumannii*) were resistant to colistin, but no resistance genes were  
282 found. There was one *E. coli* isolate resistant to cefotaxime and imipenem for which *bla*<sub>SHV</sub> and  
283 *bla*<sub>TEM</sub> were identified but carbapenem resistance genes were undetected.

## 284 DISCUSSION

285 The selection and duration of effective empirical antibiotic treatment for LRTIs have become a  
286 major challenge in LMIC settings where MDR causative bacteria are prevalent. Although  
287 culture-guided definitive treatment is often followed to avoid overuse/misuse of initial antibiotics,  
288 the long waiting time for culture results has delayed effective antibiotic therapy, posing  
289 increased risks of mortality and selection of antimicrobial resistant organisms. Rapid and  
290 inexpensive molecular PCR-based diagnostics is urgently needed in clinical practice to inform  
291 antibiotic therapy. Here, we successfully developed two EG-mPCR assays to detect and  
292 quantify 6 major bacterial pathogens and three EG-mPCR assays to identify 14 AMR genes  
293 directly from TA and sputum samples. The two PCR assays for pathogen detection exhibited  
294 high sensitivity (from 63.6% to 100%) and high specificity (from 87.5% to 97.5%) compared to  
295 conventional culture. The turnaround time from sample collection to the final PCR results was  
296 less than 6 hours.

297 A key advantage of our PCR assays is the ability to quantify the amount of each bacterium in a  
298 multiplex PCR reaction and thus could distinguish between bacterial colonization and infection.  
299 In fact, the quantitative data from the PCR assays demonstrated 100% concordance with  
300 quantitative microbiological culture results of TA samples. A previous study using a similar  
301 method raised concern about the reduced linear relationship between fluorescence levels and  
302 bacterial concentration in multiplex PCR assays, which may be attributed to the competition  
303 amongst EvaGreen dyes<sup>15</sup>. This limitation has been addressed in this work by increasing the  
304 amount of the PCR mix and adding extra EvaGreen dye to the reaction. Our experiments  
305 showed a good linear correlation ( $R^2 > 0.91$ ) between fluorescence readings and the log<sub>10</sub> of  
306 bacterial concentrations. Furthermore, the LOD of PCR assays ( $10^{3.6}$  CFU/mL) was much lower  
307 than the cut-off points for culture positivity ( $\geq 10^5$  CFU/mL), meaning our assays not only could  
308 identify true pathogens above the cut-off but also detect other potentially pathogenic bacteria  
309 present with lower concentrations for further monitoring.

310 Notably, PCR assays were able to detect more mixed target bacteria in the respiratory samples.  
311 The facts that EG-mPCR assays were more sensitive than conventional culture in detecting  
312 mixed infections, of which most target bacteria had a concentration  $> 10^5$  CFU/mL suggested  
313 that culture method may have missed some true target pathogens in the sample. Although  
314 conventional culture is considered as the gold standard for the diagnosis of bacterial LRTIs, it  
315 may be challenging to accurately recover all pathogens from a nonsterile sample. Alternatively,  
316 recent antibiotic treatment may affect the culture results and some target bacteria may present  
317 at a concentration  $< 10^5$  CFU/mL and thus not detected by culture method. Mixed bacteria by  
318 PCRs with quantitative results above the culture positivity cut-off can be regarded as a recent or  
319 current mixed infection. On the other hand, mixed bacteria by PCRs with quantitative result(s)  
320 below the cut-off should be followed up by additional PCR testing to confirm the pathogens.

321  
322 In this study, *S. pneumoniae* were only found by PCR assays in mixed infections, which was the  
323 main factor affecting the agreement between the two methods. *S. pneumoniae* was notoriously  
324 difficult to identify by conventional culture because the bacteria tends to autolyze after reaching  
325 the stationary phase, as well as the effect of prior antibiotic treatment<sup>21</sup>. Previous studies  
326 comparing multiplex PCR with culture for the detection of *S. pneumoniae* and *H. influenzae* from  
327 sputum also found similar results with *S. pneumoniae* only found by qPCR<sup>22</sup>. Our quantitative  
328 PCR assay therefore could serve as a useful diagnostic tool to detect *S. pneumoniae* from  
329 respiratory samples.

330 The use of EG-mPCR assays for AMR gene identification was also evaluated using 50 clinical  
331 samples. Overall, our findings demonstrated a high agreement between the detected AMR  
332 genes and the AMR profiles of target bacteria present in single infections. This means our  
333 assays can rapidly identify clinically relevant AMR genes to guide antibiotic therapy. As PCRs  
334 tend to detect more mixed infections, there may be some uncertainty about which AMR genes  
335 belong to which bacteria in these samples. However, the distribution of species-specific AMR  
336 genes in single infections and an understanding of local epidemiology of bacteria-drug  
337 resistance combinations can help to predict the most probable combinations of AMR gene-  
338 bacteria in mixed infections. Further research with increased sample size will provide more  
339 concrete data to discern AMR gene-bacteria combinations in mixed infections.

340 Our study has some limitations. The EG-mPCR assay had low sensitivity for the detection of *S.*  
341 *aureus*, probably due to its resistance to chemical lysis during DNA extraction<sup>23</sup>. This could be  
342 improved in future investigation by sample treatment with lysozyme and lysostaphin enzyme  
343 during DNA extraction. Here we only looked for commonly acquired AMR genes in the target  
344 bacteria, disregarding the resistance mechanisms driven by single point mutations or  
345 overexpression of efflux pump, and thus the absence of AMR genes may not always correlate  
346 with a lack of phenotype. Furthermore, as we only target 6 key pathogens, the PCR-negative  
347 samples may contain other pathogens that are not included in our PCR assays.

348 In conclusion, our multiplex realtime-PCR with EvaGreen dye MCA assays have been proven to  
349 be sensitive and quantitative for rapid detection of 6 key pathogens and 14 AMR genes directly  
350 from respiratory samples. Our assays provide culture-independent information regarding  
351 bacterial pathogens and pathogen abundance in samples as well as the genotypic AMR status  
352 of LRTIs cases. Our method can possibly distinguish colonization and infection, offering an  
353 important tool to promote the optimal use of antibiotics and to monitor the clinical and antibiotic  
354 treatment response in patients with LRITs. The PCR assays have strong potentials to be  
355 adopted in clinical practice due to its feasibility, low cost and fast turnaround time. The potential  
356 impact of our PCR assays on antibiotic therapy warrants a thorough investigation to promote its  
357 implementation in clinical practice.

358

359 **Acknowledgments**

360 We would like to thank all members of the Molecular Epidemiology group at Oxford University  
361 Clinical Research Unit (OUCRU) in Vietnam and the Microbiology Laboratory at Hospital for  
362 Tropical Diseases for their support during the conduct of the study.

363

#### 364 **Financial Support**

365 Dr Pham Thanh Duy is funded by Wellcome International Training Fellowship (grant number:  
366 222983/Z/21/Z). The funders had no role in study design, data collection and analysis, decision  
367 to publish, or preparation of the manuscript.

368

#### 369 **Conflicts of interest**

370 The authors declare no competing interests.

371

#### 372 **References**

- 373 1. Troeger, C. *et al.* Estimates of the global, regional, and national morbidity, mortality, and  
374 aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic  
375 analysis for the Global Burden of Disease Study 2016. *Lancet Infect. Dis.* **18**, 1191–1210  
376 (2018).
- 377 2. Troeger, C. *et al.* Estimates of the global, regional, and national morbidity, mortality, and  
378 aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for  
379 the Global Burden of Disease Study 2015. *Lancet Infect. Dis.* **17**, 1133–1161 (2017).
- 380 3. Cilloniz, C., Martin-Loeches, I., Garcia-Vidal, C., Jose, A. S. & Torres, A. Microbial  
381 etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. *Int. J. Mol. Sci.*  
382 **17**, (2016).
- 383 4. Wahl, B. *et al.* Burden of Streptococcus pneumoniae and Haemophilus influenzae type b  
384 disease in children in the era of conjugate vaccines: global, regional, and national  
385 estimates for 2000–15. *Lancet Glob. Heal.* **6**, e744–e757 (2018).

- 386 5. Guitor, A. K. & Wright, G. D. Antimicrobial Resistance and Respiratory Infections. *Chest*  
387 **154**, 1202–1212 (2018).
- 388 6. Metlay, J. P. & Singer, D. E. Outcomes in lower respiratory tract infections and the impact  
389 of antimicrobial drug resistance. *Clin. Microbiol. Infect.* **8**, 1–11 (2002).
- 390 7. Iregui, M., Ward, S., Sherman, G., Fraser, V. J. & Kollef, M. H. Clinical importance of  
391 delays in the initiation of appropriate antibiotic treatment for ventilator-associated  
392 pneumonia. *Chest* (2002) doi:10.1378/chest.122.1.262.
- 393 8. Metlay, J. P. & Singer, D. E. Outcomes in lower respiratory tract infections and the impact  
394 of antimicrobial drug resistance. *Clin. Microbiol. Infect.* (2002) doi:10.1046/j.1469-  
395 0691.8.s.2.4.x.
- 396 9. Calderaro, A. *et al.* Respiratory Tract Infections and Laboratory Diagnostic Methods: A  
397 Review with A Focus on Syndromic Panel-Based Assays. *Microorganisms* **10**, (2022).
- 398 10. Zhao, C. *et al.* Development of a TaqMan Array card to target 21 purulent meningitis-  
399 related pathogens. *BMC Infect. Dis.* **19**, 1–10 (2019).
- 400 11. Liu, J. *et al.* A laboratory-developed taqman array card for simultaneous detection of 19  
401 enteropathogens. *J. Clin. Microbiol.* **51**, 472–480 (2013).
- 402 12. Murphy, C. N. *et al.* Multicenter evaluation of the BioFire FilmArray Pneumonia/  
403 Pneumonia plus panel for detection and quantification of agents of lower respiratory tract  
404 infection. *J. Clin. Microbiol.* **58**, 1–20 (2020).
- 405 13. Van Der Westhuyzen, M., Samodien, N., Brink, A. J. & Moodley, C. Utility of the  
406 BioFire® FilmArray® Pneumonia Panel plus assay for syndromic testing of lower  
407 respiratory tract infections in a low/middle-income setting . *JAC-Antimicrobial Resist.* **5**,  
408 1–8 (2022).
- 409 14. Mao, F., Leung, W. Y. & Xin, X. Characterization of EvaGreen and the implication of its  
410 physicochemical properties for qPCR applications. *BMC Biotechnol.* **7**, 1–16 (2007).
- 411 15. Hu, L., Han, B., Tong, Q., Xiao, H. & Cao, D. Detection of Eight Respiratory Bacterial

- 412 Pathogens Based on Multiplex Real-Time PCR with Fluorescence Melting Curve  
413 Analysis. *Can. J. Infect. Dis. Med. Microbiol.* **2020**, (2020).
- 414 16. Anbazhagan, D. *et al.* Development of conventional and real-time multiplex PCR assays  
415 for the detection of nosocomial pathogens. *Brazilian J. Microbiol.* **42**, 448–458 (2011).
- 416 17. Molina, F. *et al.* Improved detection of Escherichia coli and coliform bacteria by multiplex  
417 PCR. *BMC Biotechnol.* **2015 151** **15**, 1–9 (2015).
- 418 18. McConnell, M. J. *et al.* Quantitative real-time PCR for detection of Acinetobacter  
419 baumannii colonization in the hospital environment. *J. Clin. Microbiol.* **50**, 1412–1414  
420 (2012).
- 421 19. Edwards, T. *et al.* Speciation of common Gram-negative pathogens using a highly  
422 multiplexed high resolution melt curve assay. *Sci. Rep.* **8**, 8–15 (2018).
- 423 20. Watson, P. F. & Petrie, A. Method agreement analysis: A review of correct methodology.  
424 *Theriogenology* **73**, 1167–1179 (2010).
- 425 21. Musher, D. M. *et al.* Can an etiologic agent be identified in adults who are hospitalized for  
426 community-acquired pneumonia: Results of a one-year study. *J. Infect.* **67**, 11–18 (2013).
- 427 22. Edin, A. *et al.* Development and laboratory evaluation of a real-time PCR assay for  
428 detecting viruses and bacteria of relevance for community-acquired pneumonia. *J. Mol.*  
429 *Diagnostics* **17**, 315–324 (2015).
- 430 23. Chapaval, L., Moon, D. H., Gomes, J. E., Duarte, F. R. & Tsai, S. M. An alternative  
431 method for Staphylococcus aureus DNA isolation. *Arq. Bras. Med. Vet. e Zootec.* **60**,  
432 299–306 (2008).

433

434

435

436



437

438 **Figures and Tables:**

439 **Figure 1.** Melting curve analysis showing the melting temperature peaks (T<sub>m</sub>) of 14 AMR genes  
440 (A, B, C) and 6 bacterial pathogens (D, E) and negative control (NTC) in 5 multiplex PCRs.

441  
442 **Figure 2.** The sensitivity of simultaneous detection of *S. aureus*, *S. pneumoniae*, *E. coli* (A) and  
443 *A. baumannii*, *K. pneumoniae*, *P. aeruginosa* (B) with concentrations ranging 10<sup>6</sup> to 12.8  
444 CFU/ml. LOD of simultaneous detection of DNA of *S. aureus*, *S. pneumoniae*, *E. coli* was 1600  
445 CFU/ml and the same for *A. baumannii*, *K. pneumoniae*, *P. aeruginosa*.

446  
447 **Figure 3.** Heatmap of bacterial mixed infection pattern detected by the EG-mPCR method in the  
448 clinical samples.

449  
450 **Figure 4.** The detection and quantity of 6 target bacteria by EG-mPCR assays in accordance  
451 with culture results (culture-negative, culture-positive with one target bacterium, culture-positive  
452 with at least two target bacteria)

453  
454 **Figure 5.** The distribution of predicted AMR genes in co-infections

455  
456 **Figure 6.** The antimicrobial susceptibility testing results of target bacteria.

457  
458 **Table 1.** Sequences, concentrations of primers used for singleplex and multiplex real-time PCR  
459 assays


460 **Table 2.** T<sub>m</sub> values of primers used for singleplex and multiplex real-time PCR assays

461 **Table 3.** Performance of EG-mPCR assays compared with the conventional culture method

462 **Table 4.** Distribution of AMR genes in single infections identified by PCR assays


463

464




**Figure 1.** Melting curve analysis showing the melting temperature peaks ( $T_m$ ) of 14 AMR genes (A, B, C) and 6 bacterial pathogens (D, E) and negative control (NTC) in 5 multiplex PCRs.

465  
466  
467  
468  
469  
470  
471  
472  
473  
474




**Figure 2.** The sensitivity of simultaneous detection of *S. aureus*, *S. pneumoniae*, *E. coli* (A) and *A. baumannii*, *K. pneumoniae*, *P. aeruginosa* (B) with concentrations ranging  $10^6$  to 12.8 CFU/ml. LOD of simultaneous detection of DNA of *S. aureus*, *S. pneumoniae*, *E. coli* was 1600 CFU/ml and the same for *A. baumannii*, *K. pneumoniae*, *P. aeruginosa*.

475  
476  
477




**Figure 3.** Heatmap of bacterial mixed infection pattern detected by the EG-mPCR method in the clinical samples

478




**Figure 4.** The detection and quantity of 6 target bacteria by EG-mPCR assays in accordance with culture results (culture-negative, culture-positive with one target bacterium, culture-positive with at least two target bacteria)

479  
480



**Figure 5.** The distribution of predicted AMR genes in co-infections

481  
482



**Figure 6.** The antimicrobial susceptibility testing results of target bacteria

483

484

485

486 **Tables**

487 **Table 1.** Sequences, concentrations of primers used for singleplex and multiplex real-time PCR  
488 assays

Primer	Gene	Sequence (5'-3')	Amplicon size (bp)	Final conc.( $\mu$ M)	Reference
<b>Pathogen detection assays</b>					
A. baumannii-F	ompA	GTAAAGGCGACGTAGACG	194		McConnell et al, 2012
A. baumannii-R		TCAGAAGTACCACGTGTACCA			
P. aeruginosa-F	oatA	GAACTGCTCTCCACCGACA	170		Edwards et al., 2018
P. aeruginosa-R		GCTGGTTCCTGATGGAGCC			
K. pneumoniae-F	khe	AGGGTTCGAGTTTGCTGCT	171		Edwards et al., 2018
K. pneumoniae-R		AGACAACCGCGTAGGCATT			
<hr/>					
E. coli-F	yaiO	TGATTTCCGTGCGTCTGAATG	115		Molina et al., 2015
E. coli-R		ATGCTGCCGTAGCGTGTTC			
S. aureus-F	sa442	GTTCCCTTCATTATCACAC	198		Anbazhagan et al., 2011
S. aureus-R		TTCATTTTACGGTGACTTCT			
S. pneumoniae-F	ply	GAATTCCTGTCTTTTCAAAG TC	106		Anbazhagan et al., 2011
S. pneumoniae-R		GACCTTGTTAGAGAATAATCC CA			
<hr/>					
<b>AMR gene detection assays</b>					
mecA-F	mecA	GGCATCGTTCCAAAGAATGT	128		this study
mecA-R		AGTGAACGAAGGTATCATCT T			
ermB-F	ermB	GTCTCGATTCCAGCAATTG	171		
ermB-R		CAGTTGACGATATTCTCGAT			
OXA-48-F	bla <sub>OXA-48</sub>	GCGTGTATTAGCCTTATCGG	204		this study
OXA-48-R		GCGGGTAAAAATGCTTGGT			
CTX-M-9-F	bla <sub>CTX-M-9</sub>	GTGCTTTATCGCGGTGA	128		this study
CTX-M-9-R		GCAGGCTTGATCTCGACAGG			
SHV-F	bla <sub>SHV</sub>	GGTGGATGCCGGTGACGA			this study
SHV-R		TCGGCAAGGTGTTTTTCGC			
<hr/>					
OXA-23-F	bla <sub>OXA-23</sub>	ACTTGCTATGTGGTTGCTTC	106		this study
OXA-23-R		GAATCACCTGATTATGTCCTT TCGTATCGCTATGTGCTAAAG			
mcr-1-F	mcr-1	TCGGTCTGTAGGGCATTG	128		this study
mcr-1-R		TCGGTCTGTAGGGCATTG			
TEM-F	bla <sub>TEM</sub>	CCCTTTTTGCGGCATTTTGC	163		this study
TEM-R		TTGGAAAACGTTCTTCGGGG			
NDM-F	bla <sub>NDM</sub>	GACAATATCACCGTTGGGAT	113		this study
NDM-R		TAGTGCTCAGTGTCGGCAT			

mphA-F		AACTGTACGCACTTGCAG		
mphA-R	mphA	CAGCACCCGCGCCTCTGGTT	179	this study
<hr/>				
IMP-F		GGTTTAAAYAAAACAACCACC		
IMP-R	bla <sub>IMP</sub>	GGAATAGAGTGGCTTAAYTCT C	189	this study
VanA-F		TGTTTGGGGTTGCTCAGA		
VanA-R	VanA	TATCCGGCGAGAGTACTGC	190	this study
CTX-M-1-F		ACCACCAACGATATCGCGG		
CTX-M-1-R	bla <sub>CTX-M-1</sub>	TACAAACCGTCGGTGACGAT	143	this study
KPC-F		TCGTGCGGAACCATTTC		
KPC-R	bla <sub>KPC</sub>	ACAGTGGGAAGCGCTCCTC	100	this study

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513



514 **Table 2.** T<sub>m</sub> values of primers used for singleplex and multiplex real-time PCR assays

Primer	Gene	Intra-assay T <sub>m</sub>	Inter-assay T <sub>m</sub>	Intra-assay CV%	Inter-assay CV%
<b>Pathogen detection assays</b>					
A. baumannii-F	ompA	80.6 ± 0.2	80.75 ± 0.27	0.3	0.3
A. baumannii-R					
P. aeruginosa-F	oatA	87.6 ± 0.3	87.7 ± 0.3	0.4	0.5
P. aeruginosa-R					
K. pneumoniae-F	khe	84.2 ± 0.3	84.22 ± 0.4	0.3	0.3
K. pneumoniae-R					
-----					
E. coli-F	yaiO	86.8 ± 0.1	86.95 ± 0.4	0.2	0.4
E. coli-R					
S. aureus-F	sa442	79 ± 0.16	79.12 ± 0.3	0.2	0.3
S. aureus-R					
S. pneumoniae-F	ply	84.49 ± 0.13	84.66 ± 0.3	0.1	0.4
S. pneumoniae-R					
-----					
<b>AMR gene detection assays</b>					
mecA-F	mecA	76.49 ± 0.14	76.44 ± 0.7	0.19	0.92
mecA-R					
ermB-F	ermB	79.83 ± 0.19	79.77 ± 0.73	0.24	0.91
ermB-R					
OXA-48-F	bla <sub>OXA-48</sub>	82.9 ± 0.08	81.98 ± 0.72	0.09	0.88
OXA-48-R					
CTX-M-9-F	bla <sub>CTX-M-9</sub>	84.72 ± 0.1	84.66 ± 0.69	0.12	0.81
CTX-M-9-R					
SHV-F	bla <sub>SHV</sub>	88.27 ± 0.1	87.85 ± 0.49	0.11	0.55
SHV-R					
-----					
OXA-23-F	bla <sub>OXA-23</sub>	78.26 ± 0.11	77.98 ± 0.39	0.14	0.51
OXA-23-R					
mcr-1-F	mcr-1	81.8 ± 0.13	81.43 ± 0.55	0.16	0.67
mcr-1-R					
TEM-F	bla <sub>TEM</sub>	83.77 ± 0.16	83.41 ± 0.55	0.19	0.66
TEM-R					
NDM-F	bla <sub>NDM</sub>	87.22 ± 0.11	86.87 ± 0.54	0.12	0.62
NDM-R					
mphA-F	mphA	89.43 ± 0.19	89.12 ± 0.46	0.22	0.51
mphA-R					
-----					
IMP-F	bla <sub>IMP</sub>	78.14 ± 0.15	78.68 ± 0.55	0.2	0.7

IMP-R					
VanA-F	VanA	82.21 ± 0.22	82.61 ± 0.42	0.26	0.51
VanA-R					
CTX-M-1-F	bla <sub>CTX-M-1</sub>	85.69 ± 0.04	86.15 ± 0.57	0.04	0.66
CTX-M-1-R					
KPC-F	bla <sub>KPC</sub>	88.78 ± 0.5	89.4 ± 0.63	0.57	0.7
KPC-R					

---

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541 **Table 3.** Performance of EG-mPCR assays compared with the conventional culture method

Bacterial pathogens	EG-mPCR	Conventional culture method		Sensitivity (%)	Specificity (%)	PPV (%)	NPV(%)	Kappa
		positive	negative					
K. pneumoniae	positive	10	1	100	97.50	90.9	100	0.94
	negative	0	39					
A. baumannii	positive	14	1	100	97.22	93.3	100	0.95
	negative	0	35					
P. aeruginosa	positive	18	4	100	87.50	81.8	100	0.8
	negative	0	28					
E. coli	positive	2	2	100	95.83	50	100	0.65
	negative	0	46					
S. aureus	positive	7	2	63.64	94.87	77.8	100	0.63
	negative	4	37					

542

543 **Table 4.** Distribution of AMR genes in single infections identified by PCR assays

544

Pathogens detected by culture (n)	n	Cephalosporin resistance	Carbapenem resistance	Macrolide resistance	
		resistant genes	n resistant genes	n resistant genes	
<i>A. baumannii</i> (9)	7	TEM (7/7)	7	OXA23 (7/7)	
Gram negative	4	TEM (3/4)	2	NDM (2/2)	
		CTXM-1 (1/4)		OXA-48 (2/2)	
		<i>E. coli</i> (2)	1	1	
Gram positive	1	TEM (1/1)	1	OXA23 (1/1)	
		<i>P. aeruginosa</i> (9)		1	1
<i>S. aureus</i> (5)*				5	emrB (3/5)

545 \* EG-mPCR detected 3 *S. aureus* and did not identify 2 *S. aureus* in single-infection cases.

546

547

548

549

550

551

552